.png)
Our client, a Doctor of Dental Surgery, was the subject of a multi-state investigation that spanned nearly three years. The time and operational drag on the business arising from these investigations was significant, but the Prosecution Division of the Pennsylvania Department of State's Office of Chief Counsel recently closed their file on this matter with no further action or licensing implications.
Telemedicine is an Enforcement Risk Factor
Using our background as former prosecutors, federal investigators, and government regulators, HLA advises a wide spectrum of clients across the healthcare delivery chain on how to take risk in a safe and compliant manner.
Although there a number of factors that potentially increase risk in the highly regulated healthcare industry, the Department of Justice and supporting agencies, such as HHS-OIG and the FBI, have prioritized civil and criminal investigations relating to telemedicine in recent years.
Telemedicine is often the subject of federal focus because it typically crosses state lines and involves relatively high claim volume.
HLA's Defense Strategy
In this case, we helped the investigative agencies to understand the telemedicine space in great detail, which provided context for our arguments that the client's business model was fully compliant with all applicable laws and regulations.
In the healthcare industry, there is a lot of "grey," which provides for innovation and business opportunities. At the same time, if you or your business are seeking to capitalize on those opportunities, it is critical to have a compelling narrative that will address any regulatory concerns in the event of scrutiny. Reliance on experienced defense counsel often helps to support that narrative.
State Officials Declined to Prosecute
Based on our factual and legal arguments, multiple state licensing boards, including the Pennsylvania Department most recently, declined to take further action and closed their file. Now our satisfied client can refocus his energy where it should be, on running his business.
MORE ARTICLES BY CATEGORY
The 2025 Healthcare Fraud Takedown Is a Warning Shot for Wound Care Providers
Wound care is now an enforcement priority. The 2025 fraud takedown targets skin substitute billing, graft utilization, and Medicare compliance.
Read More >>FDA and Novo’s Uncharted Waters to Exert Pressure on Hims & Hers and GLP-1 Compounders
Novo’s lawsuit against Hims & Hers, coupled with FDA’s referral to the DOJ, marks a direct escalation against 503A compounded semaglutide. If your pharmacy dispenses, compounds, or markets GLP-1 therapies, this is not a headline, it is a regulatory turning point.
Read More >>What Wells Pharma v. Zyla Life Sciences Means for Compounding Pharmacies and Outsourcing Facilities
A pending Supreme Court case could reshape how compounding pharmacies face litigation under state unfair competition laws tied to FDA approval standards.
Read More >>Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel
Health Law Alliance adds powerhouse Pharmacist/Attorney Dr. Martha Rumore to their team of boutique healthcare attorneys.
Read More >>







